Pfizer Ireland Plant Receives ISPE Award
Pfizer's addition of a new vaccine suite and multiproduct bioprocess suite to its Ireland facility win the company the title of 2014 Facility of the Year.
The International Society for Pharmaceutical Engineers (ISPE) recognized Pfizer Ireland as the overall winner in the 2014 Facility of the Year Awards (FOYA) category at the society’s annual meeting in Las Vegas, Nevada. FOYA acknowledges the pharmaceutical manufacturing industry’s accomplishments in construction and facility design and the pursuit of new technologies.
The focus of Pfizer Ireland’s Network Strategy Implementation (NSI) Capacity project was the addition of a new vaccine suite and a drug substance bioprocess suite. The new manufacturing suites included the latest technologies, including electronic batch records, process analytical technology, and disposable bag processing. Pfizer Ireland conducted the project using a lean management strategy, a 5S program in the design process, and a Six Sigma toolkit. The Pfizer Ireland Grange Castle plant that won the award is located in Clondalkin, South County Dublin.
“The society was impressed with the NSI Capacity Expansion project and the company’s ability to effectively manage the challenges of maintaining supply with the demolition of existing facilities, new construction, and start-up and integration activities,” said Chair of the FOYA Judging Panel James Breen in a press release.
SOURCE: ISPE
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
